---
title: "Gilead Sciences Inc. Stock Outperforms Competitors Despite Losses On The Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292673095.md"
description: "Gilead Sciences Inc. (GILD) stock fell 1.04% to $130.04 on Tuesday, underperforming the broader market as the S&P 500 and Dow Jones rose. Despite this daily decline, Gilead outperformed key competitors Johnson & Johnson, Pfizer, and Abbott Laboratories, which all posted larger losses. The stock remains 17.32% below its 52-week high, with trading volume notably lower than its 50-day average."
datetime: "2026-07-14T20:35:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292673095.md)
  - [en](https://longbridge.com/en/news/292673095.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292673095.md)
generator: "portal-rs"
---

# Gilead Sciences Inc. Stock Outperforms Competitors Despite Losses On The Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Gilead Sciences Inc. (GILD) slipped 1.04% to $130.04 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.38% to 7,543.59 and the Dow Jones Industrial Average rising 0.02% to 52,508.27.

Gilead Sciences Inc. closed 17.32% below its 52-week high of $157.29, which the company reached on February 11th.

The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Johnson & Johnson (JNJ) fell 1.52% to $253.85, Pfizer Inc. (PFE) fell 0.94% to $24.25, and Abbott Laboratories (ABT) fell 3.42% to $88.96.

Trading volume (5.2 M) remained 2.7 million below its 50-day average volume of 7.9 M.

Data source: Dow Jones Market Data, FactSet. Data compiled July 14, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

07-14-26 1635ET

### Related Stocks

- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Parallax Volatility Advisers L.P. Trims Holdings in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/297162579.md)
- [New HIV and Breast Cancer Wins Might Change The Case For Investing In Gilead Sciences (GILD)](https://longbridge.com/en/news/297483843.md)
- [Gilead breaks ground on Foster City biologics facility in $32 billion US investment push](https://longbridge.com/en/news/297254548.md)
- [FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients](https://longbridge.com/en/news/297236507.md)
- [European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status | GILD Stock News](https://longbridge.com/en/news/296773236.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**